查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1836926

可吸收血管支架市场（依适应症、材料、最终用户、支架直径和支架长度）－全球预测，2025-2032

Resorbable Vascular Scaffold Market by Indication, Material, End User, Scaffold Diameter, Scaffold Length - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

可吸收血管支架市场预计到 2032 年将成长至 16.6585 亿美元，复合年增长率为 14.18%。

主要市场统计数据
基准年2024年 5.7657亿美元
预计2025年 6.5695亿美元
预测年份：2032年 16.6585亿美元
复合年增长率（%） 14.18%

对可吸收血管支架的临床机会、工程原理、监管格局和相关人员动态的权威介绍

可吸收血管支架代表了材料科学与介入性心臟病学的融合，旨在恢復血管通畅性并消除金属植入的长期存在。其设计原理是在血管逐渐吸收之前的癒合期间提供临时机械支撑和可控的药物洗脱，这可能会减轻与永久性植入相关的晚期不利事件。本导论分析描述了技术发展、临床驱动因素以及相关人员的生态系统，这些因素共同决定了临床整合的步伐。

临床医生、设备工程师、监管机构和医院采购团队在价值创造和风险降低方面各自扮演不同的角色。临床医师需要确凿的证据来证明其在急性冠状动脉疾病、慢性冠状动脉疾病和周边动脉疾病的安全性和有效性。工程师追求更薄的支撑几何形状、可预测的劣化特性和优化的药物-聚合物基质，以提高输送能力血管再阻塞。监管机构优先考虑长期追踪和影像学终点，而采购方则考虑手术成本、库存复杂性和报销调整。这些因素共同决定了产品开发、临床试验设计和上市策略，并决定了哪些支架概念能够进入常规临床应用。

定义构成可吸收血管支架模式的材料科学、程序实践和临床证据的令人困惑的模式

可吸收血管支架的前景正从概念性前景发展到实际工程和临床改进。生物可吸收材料（例如镁合金和聚乳酸衍生物）的进步，提高了其径向强度、降解速率和生物相容性。同时，器械结构的不断改进，包括更薄的支撑桿、更坚固的支架几何形状以及下一代药物涂层，缓解了早期对支架血栓症和血管回缩的担忧。血管内成像和操作技术的改进降低了支架部署的可变性，而从药物释放型支架中获得的多学科经验也为最佳抗血小板策略和植入实践提供了参考。

不仅材料和技术日趋成熟，证据基础也日趋完善。上市后註册和重点随机试验不断缩小可吸收支架能够带来增量效益的临床应用范围。监管方法也不断演变，以平衡快速获取和可靠的长期安全性数据的需求，鼓励製造商将长期追踪和影像学终点纳入研发路径。从经济角度来看，医院和付款方越来越要求明确的价值陈述，以减少长期併发症并简化终身影像学和干预措施。这些变革性转变正在共同调整研发重点，影响报销谈判，并缩短从原型到临床应用的时间，从而显着改善患者预后。

评估 2025 年美国关税对国际可吸收血管支架供应链的综合营运、采购和创新影响

对医疗设备组件和成品征收关税可能会对可吸收血管支架的开发和商业化产生多方面的影响。关税带来的成本压力可能会增加依赖国际供应链获取关键投入（例如特种合金、聚合物原材料和精密製造设备）的製造商的采购复杂性。这可能会导致协议价格和利润率压缩，从而推迟临床试验、生产规模扩大和全球市场进入计画的投资。此外，报销谈判将越来越多地考虑总护理成本和生命週期经济效益，而不仅仅是单位成本。

应对关税中断的策略措施包括近岸外包零件製造、重新协商供应商合约以及重新设计以提高材料采购的灵活性。虽然这些措施需要前置作业时间和资本配置，但它们可以增强对未来政策波动的抵御能力。此外，医疗设备开发商可以透过加快开发成本效益高的生产流程或优先考虑具有优惠条件的市场来维持商业性发展势头。临床采用路径可能会随着时间的推移而变化，因为医疗保健提供者会权衡可吸收解决方案的临床效益与短期预算限制，从而在不同地区和医疗机构之间创造差异化的机会窗口。

针对临床适应症、支架材料、设备尺寸和最终用户设定进行细分洞察，以塑造治疗途径和采用

细分视角揭示了适应症、材料、最终用户情况、支架直径和支架长度如何影响临床选择、装置设计优先顺序和商业性定位。临床环境基于适应症范围，涵盖冠状动脉疾病和周边动脉疾病，其中冠状动脉疾病进一步分为急性冠状动脉症候群和稳定型心绞痛，外周动脉疾病则分为跛行和严重肢体缺血。急性冠状动脉介入治疗通常优先考虑快速输送和可控吸收以支持早期癒合，而周边肢体缺血介入治疗则需要长期径向强度和增强的抗压缩力耐久性。

镁和聚乳酸之间的材料细分在强度、降解时间和生物相容性方面存在不同的权衡，这体现在器械的操作和成像性能上。最终用户细分，例如门诊手术中心、心臟中心和医院，导致手术量、基础设施和采购週期存在差异，进而影响库存策略和销售模式。支架直径细分为小于3毫米和大于3毫米两类，直接影响器械的几何形状和临床适应症。支架长度细分为18-28毫米、大于28毫米和小于18毫米的托槽，影响输送系统、复製策略和库存范围。因此，製造商必须根据特定的临床适应症和最终用户工作流程定製材料选择和尺寸平台，以优化采用率和经济效益。

整合美洲、欧洲、中东和非洲地区以及亚太地区的临床基础设施、法律规范、报销动态和采用模式的区域观点

美洲、欧洲、中东和非洲以及亚太地区的临床基础设施、法律规范、报销途径和从业者偏好，塑造了截然不同的区域绩效和应用动态。美洲地区拥有高度集中的介入专家和大量的冠状动脉项目，有助于快速的程序学习和早期应用。该地区的监管途径和付款人谈判强调强大的临床终点和长期安全性，从而奖励製造商提供成熟的上市后证据以及随机数据。

在欧洲、中东和非洲，管理体制和报销模式的差异导致可吸收支架的可近性参差不齐。一些司法管辖区优先考虑卫生技术评估标准和长期成本效益，从而促使製定客製化的市场进入策略。亚太地区的市场临床能力参差不齐，但手术量增长率较高，扩充性的生产和本地监管部门的参与，加上临床医生培训项目，可以加速可吸收支架的采用。在任何地区，血管内成像基础设施、操作人员培训生态系统以及本地报销政策的细微差别都将决定可吸收支架从专科中心推广到广泛临床应用的速度。因此，制定差异化的区域策略，将证据产生和商业化投资与当地临床和付款方的优先事项相结合，对于持续采用至关重要。

关于支架製造商伙伴关係、临床管线、生产规模、智慧财产权定位和竞争差异化的策略企业资料

可吸收血管支架开发公司之间的竞争态势取决于临床证据的产生、生产规模、差异化的智慧财产权以及商业伙伴关係关係。领先的开发商凭藉强大的临床管线，在各种冠状动脉和周边血管疾病适应症中展现出安全性，从而脱颖而出；而其他开发商则优先考虑製造能力，以确保设备性能的一致性和法规合规性。与影像公司、契约製造製造商和临床研究机构的合作可以加速证据产生并简化市场进入流程，而公司内部的精密挤压和灭菌能力则可以实现品质和成本控制。

企业策略越来越多地纳入与医院系统和专家网路的共同开发契约，以确保真实世界数据的承诺和应用途径。许可安排和选择性併购可以扩展材料科学的能力和地理覆盖范围，但也需要精心的整合规划才能保持临床发展势头。聚合物配方、合金加工和支架结构的智慧财产权地位仍然是与潜在合作伙伴谈判的战略资产和筹码。对于公司和投资者而言，成功取决于将临床概念验证与可扩展的生产和有针对性的商业部署同步进行，以反映最终用户的需求和不同的区域准入条件。

为製造商、临床医生和投资者提供可行的建议，以加速临床应用并降低商业性和程序风险

产业领导者可以采取具体行动，在管理临床和商业不确定性的同时，加速技术应用。首先，将临床开发项目与差异化的适应症路径结合。优先考虑那些具有高影响力、短期立足就能带来明确治疗益处的演示，并设计结合影像学和患者报告结果的试验，以强化价值故事。其次，透过多元化原料采购和评估本地製造中心来投资供应链韧性，以减少贸易政策衝击的影响，并确保向大批量生产地点提供可预测的设备供应。

第三，我们将积极与付款方和健康科技评估机构合作，建立能够反映医疗总成本和长期效益的报销模式。第四，我们将开发临床医生教育项目，将影像引导的植入方案与实践培训相结合，以减少手术差异并改善疗效。第五，我们将建立策略伙伴关係，将材料专业知识、生产规模和临床试验基础设施结合，以加快上市时间并维持品质。最后，我们将采取分阶段的商业化策略，首先将重点放在卓越中心的初始市场进入，然后再进行更广泛的推广，以累积真实世界证据，并根据早期绩效数据完善定价和服务模式。

融合主要专家访谈、临床文献回顾、註册分析与供应链检验的混合方法研究途径

本分析背后的调查方法融合了定性和定量分析，以确保获得可靠且可操作的见解。主要研究包括对介入性心臟病专家、週边血管专家、采购负责人和监管专家进行结构化访谈，以了解该领域对器械性能、操作流程和采购优先顺序的观点。次要研究则包括对同行评审的临床文献、器械註册登记、监管备案和专利出版物进行系统性回顾，以揭示临床结果、安全讯号和创新趋势之间的三角关係。

供应链图谱识别了关键的投入依赖关係和製造瓶颈，而商业管道分析则探讨了医院采购流程和潜在的最终用户采用情况。研究结果经专家顾问小组检验，并在可用的情况下与长期设备性能报告进行交叉引用。在整个过程中，我们强调资料来源、调查方法和资料来源的透明度，以确保结论可复製并适用于营运规划。这种混合方法所得出的见解既具有临床相关性，又具有商业性可行性。

对影响可吸收支架发展轨迹和商业性成功的策略要务、持续存在的障碍和关键成功因素的总结性综合

总而言之，可吸收血管支架在临床应用前景和工程创新之间有着令人瞩目的联繫，但其能否成功应用于常规实践，取决于材料科学、证据生成、监管策略和商业性执行等方面的协同进步。仍存在一些持续存在的障碍，包括对长期安全资料的需求、应对贸易政策波动的供应链韧性，以及考虑生命週期效益而非仅考虑单位成本的清晰支付途径。然而，如果这些障碍得到解决，支架技术有可能改变冠状动脉和周边疾病的治疗模式。

成功之路需要器械设计与临床适应症之间的严谨协调，有针对性地产生证据以回应相关人员的关切，并进行商业投资以确保可靠的生产和分销。能够将临床领导力与灵活的供应链策略和清晰的报销价值提案相结合的组织，将最有可能实现可吸收支架的临床和商业性效益。最终，结合实用的手术流程、可证实的患者获益和永续的经济效益的器械将决定这项技术在血管介入领域的长期作用。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 生物可吸收镁支架原型提供增强的机械支撑和可控的降解速率
  • 整合血管内成像技术，优化支架放置，最大程度降低不合规风险
  • 聚合物基和金属生物可吸收支架平台的长期临床结果比较
  • 成本效用分析评估生物可吸收支架的总治疗成本和品质调整生命年
  • 亚太地区监理核准加速，将推动下一代可吸收支架设备的采用
  • 开发结合基因治疗载体和抗增生药物的双重治疗支架，用于预防血管再阻塞
  • 利用先进的 3D 列印和影像数据，根据患者特定的冠状动脉解剖结构进行个人化支架设计
  • 可生物降解产品对血管癒合和全身性发炎反应特征的永续性影响

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 可吸收血管支架市场（按适应症）

  • 冠状动脉疾病
    • 急性冠状动脉症候群
    • 稳定型心绞痛
  • 周边动脉疾病
    • 跛足
    • 危急性肢体缺血

9. 可吸收血管支架市场（依材料）

  • 镁
  • 聚乳酸

第 10 章。可吸收血管支架市场（按最终用户）

  • 门诊手术中心
  • 心臟中心
  • 医院

11. 可吸收血管支架市场（依支架直径）

  • 小于3毫米
  • 3毫米或以上

12. 可吸收血管支架市场（依支架长度）

  • 18至28毫米
  • 28毫米或以上
  • 小于18毫米

第十三章可吸收血管支架市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 14 章可吸收血管支架市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章可吸收血管支架市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Abbott Laboratories
    • Boston Scientific Corporation
    • Biotronik SE & Co. KG
    • Terumo Corporation
    • Meril Life Sciences Private Limited
    • Elixir Medical Corporation
    • Xeltis AG
    • Cardionovum GmbH
    • MicroPort Scientific Corporation
    • Zorion Medical
Product Code: MRR-035AB9C0DAAB

The Resorbable Vascular Scaffold Market is projected to grow by USD 1,665.85 million at a CAGR of 14.18% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 576.57 million
Estimated Year [2025] USD 656.95 million
Forecast Year [2032] USD 1,665.85 million
CAGR (%) 14.18%

An authoritative introduction to clinical opportunity, engineering principles, regulatory landscape, stakeholder dynamics around resorbable vascular scaffolds

Resorbable vascular scaffolds represent a convergence of materials science and interventional cardiology intended to restore vessel patency while eliminating the long-term presence of a permanent metallic implant. The design rationale is to provide transient mechanical support and controlled drug elution during the period of vessel healing before gradual resorption, thereby potentially reducing late adverse events linked to permanent implants. This introductory analysis contextualizes technological evolution, clinical drivers, and the stakeholder ecosystem that together determine the pace of clinical integration.

Clinicians, device engineers, regulatory authorities, and hospital procurement teams each play a distinct role in value creation and risk mitigation. Clinicians demand robust safety and efficacy evidence across acute and chronic coronary presentations as well as peripheral arterial conditions. Engineers pursue thinner strut geometry, predictable degradation profiles, and optimized drug-polymer matrices to improve deliverability and reduce restenosis. Regulators emphasize long-term follow-up and imaging endpoints, while purchasers weigh procedural cost, inventory complexity, and reimbursement alignment. Taken together, these forces set the agenda for product development, clinical trial design, and go-to-market strategies that will define which scaffold concepts progress to routine clinical use.

Defining disruptive inflection points in materials science, procedural practice, and clinical evidence reshaping the resorbable vascular scaffold landscape

The landscape for resorbable vascular scaffolds has shifted from conceptual promise to pragmatic engineering and clinical refinement. Advances in bioresorbable materials such as magnesium alloys and polylactic acid derivatives have improved radial strength, controlled degradation kinetics, and biocompatibility. Simultaneously, iterative improvements in device architecture-thinner struts, enhanced scaffold geometries, and next-generation drug coatings-have mitigated early concerns around scaffold thrombosis and vessel recoil. Improved intravascular imaging and procedural techniques have reduced deployment variability, and cross-disciplinary learning from drug-eluting stents has informed optimal antiplatelet strategies and implantation best practices.

Beyond materials and technique, the evidence base has matured; post-market registries and focused randomized studies continue to refine the clinical niches where resorbable scaffolds provide incremental benefit. Regulatory approaches have evolved to balance accelerated access with demands for robust longitudinal safety data, prompting manufacturers to embed extended follow-up and imaging endpoints into development pathways. Economically, hospitals and payers increasingly demand clear value narratives tied to reduced long-term complications and simplified lifelong imaging or intervention. Together, these transformative shifts are realigning R&D priorities, shaping reimbursement conversations, and compressing the time from prototype to clinical adoption for technologies that can demonstrably improve patient outcomes.

Assessing compounded operational, procurement, and innovation consequences of 2025 US tariffs on international supply chains for resorbable vascular scaffolds

The introduction of tariffs affecting medical-device components and finished goods can exert a multi-dimensional impact on resorbable vascular scaffold development and commercialization. Tariff-driven cost pressures raise procurement complexity for manufacturers that rely on international supply chains for key inputs such as specialized alloys, polymer feedstocks, and precision manufacturing equipment. In turn, consented price increases or margin compression can slow investment in clinical trials, manufacturing scale-up, and global market entry plans. Hospital procurement teams may recalibrate purchasing decisions as device pricing dynamics shift, while reimbursement negotiations will increasingly factor in total cost of care and lifecycle economics rather than unit price alone.

Strategic responses to tariff-induced disruption include near-shoring of component manufacturing, renegotiation of supplier contracts, and redesign for material sourcing flexibility. These measures require lead time and capital allocation but can increase resilience against future policy volatility. In addition, device developers may accelerate development of cost-effective production processes or prioritize markets with favorable trade terms to preserve commercial momentum. Clinical adoption pathways may experience temporal variation as providers weigh the clinical advantages of resorbable solutions against short-term budgetary constraints, creating differentiated windows of opportunity across geographies and care settings.

Segmentation-focused insights into clinical indications, scaffold materials, device dimensions, and end-user settings that shape therapeutic pathways and adoption

A segmentation lens reveals how indication, material, end-user context, scaffold diameter, and scaffold length each inform clinical selection, device design priorities, and commercial positioning. Based on indication the clinical environment spans Coronary Artery Disease and Peripheral Arterial Disease, with Coronary presentations further divided into Acute Coronary Syndrome and Stable Angina, and Peripheral presentations distinguished between Claudication and Critical Limb Ischemia. These clinical pathways demand distinct mechanical profiles and drug-elution strategies: acute coronary interventions often prioritize rapid deliverability and controlled resorption to support early healing, while peripheral limb ischemia interventions require longer-term radial strength and enhanced durability against compressive forces.

Material segmentation across Magnesium and Polylactic Acid offers different trade-offs between strength, degradation timeline, and biocompatibility, which manifest in device handling and imaging profiles. End-user segmentation encompassing Ambulatory Surgical Centers, Cardiac Centers, and Hospitals drives differences in procedural volume, infrastructure, and purchasing cycles, thereby influencing inventory strategy and sales engagement models. Scaffold diameter segmentation distinguishing Less Than 3 Millimeter and Three Millimeter And Above categories directly affects device geometry and clinical indications, while scaffold length segmentation across Eighteen To Twenty Eight Millimeter, Greater Than Twenty Eight Millimeter, and Less Than Eighteen Millimeter brackets impacts delivery systems, overlapping strategies, and inventory breadth. Consequently, manufacturers must align material choice and dimensional platforms to specific clinical indications and end-user workflows to optimize adoption and economic viability.

Regional perspectives integrating clinical infrastructure, regulatory frameworks, reimbursement dynamics, and adoption patterns across Americas, EMEA and Asia-Pacific

Regional performance and adoption dynamics differ markedly and are shaped by clinical infrastructure, regulatory frameworks, reimbursement pathways, and practitioner preferences across Americas, Europe, Middle East & Africa, and Asia-Pacific. The Americas exhibit concentrated centers of interventional expertise and high-volume coronary programs that facilitate rapid procedural learning and early adopter behavior. Regulatory pathways and payer negotiations in this region emphasize robust clinical endpoints and long-term safety, which incentivizes manufacturers to present mature post-market evidence alongside randomized data.

In Europe, Middle East & Africa, heterogeneous regulatory regimes and reimbursement models create a mosaic of access; several jurisdictions prioritize health-technology assessment criteria and long-term cost-effectiveness, prompting tailored market access strategies. Asia-Pacific includes markets with variable clinical capacity but high procedural growth, where scalable manufacturing and local regulatory engagement can accelerate penetration when coupled with clinician training programs. Across all regions, infrastructure for intravascular imaging, operator training ecosystems, and local reimbursement nuances determine the pace at which resorbable scaffolds shift from specialized centers to broader clinical practice. Consequently, a differentiated geographic strategy that aligns evidence generation and commercialization investments with regional clinical and payer priorities is essential for sustained uptake.

Strategic corporate intelligence on partnerships, clinical pipelines, manufacturing scale, IP positioning, and competitive differentiation among scaffold makers

Competitive dynamics among companies developing resorbable vascular scaffolds are shaped by clinical evidence generation, manufacturing scale, intellectual property differentiation, and commercial partnerships. Leading developers differentiate through robust clinical pipelines that demonstrate safety across diverse coronary and peripheral indications, while others emphasize manufacturing competence to ensure consistent device performance and regulatory compliance. Partnerships with imaging companies, contract manufacturers, and clinical research organizations can accelerate evidence generation and streamline market entry, whereas in-house capabilities in precision extrusion and sterilization provide control over quality and cost.

Corporate strategies increasingly include co-development agreements with hospital systems and specialist investigator networks to secure real-world data commitments and adoption pathways. Licensing arrangements and selective mergers or acquisitions can expand material science capabilities or geographic reach, but they also require careful integration planning to preserve clinical momentum. Intellectual property positioning around polymer formulations, alloy processing, and scaffold architecture remains a strategic asset and a lever in negotiations with potential partners. For companies and investors, success will hinge on the ability to synchronize clinical proof points with scalable manufacturing and targeted commercial rollouts that reflect differences in end-user requirements and regional access conditions.

Actionable recommendations for manufacturers, clinicians, and investors to accelerate clinical adoption and reduce commercial and procedural risk

Industry leaders can take concrete actions to accelerate adoption while managing clinical and commercial uncertainty. First, align clinical development programs with differentiated indication pathways; prioritize high-impact presentations where transient scaffolding offers clear therapeutic advantages and design trials that incorporate imaging and patient-reported outcomes to strengthen value narratives. Second, invest in supply chain resilience by diversifying raw material sources and evaluating localized manufacturing hubs to reduce exposure to trade policy shocks and to ensure predictable device supply to high-volume centers.

Third, engage proactively with payers and health-technology assessment bodies to establish reimbursement paradigms that reflect total cost of care and long-term benefits. Fourth, build clinician education programs that combine hands-on training with imaging-guided implantation protocols to reduce procedural variability and improve outcomes. Fifth, pursue strategic partnerships that combine materials expertise, manufacturing scale, and clinical trial infrastructure to shorten time-to-market while maintaining quality. Finally, adopt a phased commercialization strategy that sequences initial market entry into centers of excellence before broader roll-out, thereby accumulating real-world evidence and refining pricing and service models in response to early performance data.

Mixed-methods research approach integrating primary expert interviews, clinical literature review, registry analysis, and supply chain validation

The research methodology underpinning this analysis integrates qualitative and quantitative approaches to ensure robust and actionable findings. Primary research comprised structured interviews with interventional cardiologists, peripheral vascular specialists, procurement leaders, and regulatory experts to capture frontline perspectives on device performance, procedural workflows, and purchasing priorities. Secondary research included systematic review of peer-reviewed clinical literature, device registries, regulatory filings, and patent disclosures to triangulate clinical outcomes, safety signals, and technological innovation trends.

Supply chain mapping identified critical input dependencies and manufacturing bottlenecks, while commercial channel analysis examined hospital procurement processes and end-user adoption levers. Findings were validated through expert advisory panels and cross-checked with longitudinal device performance reports where available. Throughout the process, emphasis was placed on transparent documentation of data sources, methodological limitations, and assumptions to ensure that conclusions are reproducible and suitable for operational planning. This mixed-methods approach yields insights that are both clinically relevant and commercially executable.

Concluding synthesis of strategic imperatives, persistent barriers, and critical success factors shaping trajectory and commercial success of resorbable scaffolds

In conclusion, resorbable vascular scaffolds occupy a compelling nexus of clinical promise and engineering innovation, but their successful translation into routine practice depends on coordinated progress across materials science, evidence generation, regulatory strategy, and commercial execution. Persistent barriers include the need for long-term safety data, supply chain resilience in the face of trade policy fluctuations, and clear payer pathways that account for lifecycle benefits rather than unit price alone. Yet, where these barriers are addressed, scaffold technologies have the potential to change therapeutic paradigms for selected coronary and peripheral indications.

The pathway to success requires a disciplined alignment of device design with clinical indication, targeted evidence generation that responds to stakeholder concerns, and operational investments that secure reliable manufacturing and distribution. Organizations that integrate clinical leadership with agile supply chain strategies and clear reimbursement value propositions will be best positioned to realize the clinical and commercial benefits of resorbable scaffolds. Ultimately, the devices that combine practicable procedural workflows, demonstrable patient benefits, and sustainable economics will determine the technology's long-term role in vascular intervention.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emerging bioresorbable magnesium scaffold prototypes offering enhanced mechanical support and controlled degradation kinetics
  • 5.2. Integration of intravascular imaging technologies to optimize scaffold placement and minimize malapposition risks
  • 5.3. Comparative long term clinical outcomes of polymer based versus metallic bioresorbable scaffold platforms
  • 5.4. Cost utility analyses assessing total treatment cost and quality adjusted life years gained with bioresorbable scaffolds
  • 5.5. Accelerated regulatory approvals in Asia Pacific driving adoption of next generation resorbable scaffold devices
  • 5.6. Development of dual therapy scaffolds delivering antiproliferative drugs alongside gene therapy vectors for restenosis prevention
  • 5.7. Personalized scaffold designs based on patient specific coronary anatomy using advanced 3D printing and imaging data
  • 5.8. Sustainability impact of biodegradation byproducts on vascular healing and systemic inflammatory response profiles

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Resorbable Vascular Scaffold Market, by Indication

  • 8.1. Coronary Artery Disease
    • 8.1.1. Acute Coronary Syndrome
    • 8.1.2. Stable Angina
  • 8.2. Peripheral Arterial Disease
    • 8.2.1. Claudication
    • 8.2.2. Critical Limb Ischemia

9. Resorbable Vascular Scaffold Market, by Material

  • 9.1. Magnesium
  • 9.2. Polylactic Acid

10. Resorbable Vascular Scaffold Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Cardiac Centers
  • 10.3. Hospitals

11. Resorbable Vascular Scaffold Market, by Scaffold Diameter

  • 11.1. Less Than 3 Millimeter
  • 11.2. Three Millimeter And Above

12. Resorbable Vascular Scaffold Market, by Scaffold Length

  • 12.1. Eighteen To Twenty Eight Millimeter
  • 12.2. Greater Than Twenty Eight Millimeter
  • 12.3. Less Than Eighteen Millimeter

13. Resorbable Vascular Scaffold Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Resorbable Vascular Scaffold Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Resorbable Vascular Scaffold Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Abbott Laboratories
    • 16.3.2. Boston Scientific Corporation
    • 16.3.3. Biotronik SE & Co. KG
    • 16.3.4. Terumo Corporation
    • 16.3.5. Meril Life Sciences Private Limited
    • 16.3.6. Elixir Medical Corporation
    • 16.3.7. Xeltis AG
    • 16.3.8. Cardionovum GmbH
    • 16.3.9. MicroPort Scientific Corporation
    • 16.3.10. Zorion Medical

LIST OF FIGURES

  • FIGURE 1. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. RESORBABLE VASCULAR SCAFFOLD MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. RESORBABLE VASCULAR SCAFFOLD MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. RESORBABLE VASCULAR SCAFFOLD MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY STABLE ANGINA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY STABLE ANGINA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY STABLE ANGINA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY STABLE ANGINA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY STABLE ANGINA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY STABLE ANGINA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CLAUDICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CLAUDICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CLAUDICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CLAUDICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CLAUDICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CLAUDICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MAGNESIUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MAGNESIUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MAGNESIUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MAGNESIUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MAGNESIUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MAGNESIUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYLACTIC ACID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYLACTIC ACID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYLACTIC ACID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYLACTIC ACID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYLACTIC ACID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYLACTIC ACID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CARDIAC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CARDIAC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CARDIAC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CARDIAC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN 3 MILLIMETER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN 3 MILLIMETER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN 3 MILLIMETER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN 3 MILLIMETER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN 3 MILLIMETER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN 3 MILLIMETER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY THREE MILLIMETER AND ABOVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY THREE MILLIMETER AND ABOVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY THREE MILLIMETER AND ABOVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY THREE MILLIMETER AND ABOVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY THREE MILLIMETER AND ABOVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY THREE MILLIMETER AND ABOVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY EIGHTEEN TO TWENTY EIGHT MILLIMETER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY EIGHTEEN TO TWENTY EIGHT MILLIMETER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY EIGHTEEN TO TWENTY EIGHT MILLIMETER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY EIGHTEEN TO TWENTY EIGHT MILLIMETER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY EIGHTEEN TO TWENTY EIGHT MILLIMETER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY EIGHTEEN TO TWENTY EIGHT MILLIMETER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY GREATER THAN TWENTY EIGHT MILLIMETER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY GREATER THAN TWENTY EIGHT MILLIMETER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY GREATER THAN TWENTY EIGHT MILLIMETER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY GREATER THAN TWENTY EIGHT MILLIMETER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY GREATER THAN TWENTY EIGHT MILLIMETER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY GREATER THAN TWENTY EIGHT MILLIMETER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN EIGHTEEN MILLIMETER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN EIGHTEEN MILLIMETER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN EIGHTEEN MILLIMETER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN EIGHTEEN MILLIMETER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN EIGHTEEN MILLIMETER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN EIGHTEEN MILLIMETER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 119. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 121. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 123. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2025-2032 (USD MILLION)
  • TABLE 125. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 126. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 127. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 129. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2025-2032 (USD MILLION)
  • TABLE 131. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2025-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 136. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 138. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2024 (USD MILLION)
  • TABLE 140. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2025-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 142. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 144. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2024 (USD MILLION)
  • TABLE 146. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2025-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2024 (USD MILLION)
  • TABLE 148. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2025-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 152. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 154. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2024 (USD MILLION)
  • TABLE 156. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2025-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 158. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 160. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2024 (USD MILLION)
  • TABLE 162. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2025-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2024 (USD MILLION)
  • TABLE 164. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2025-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 200. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 202. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2024 (USD MILLION)
  • TABLE 204. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2025-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 206. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2025-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2024 (USD MILLION)
  • TABLE 212. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2025-2032 (USD MILLION)
  • TABLE 213. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 216. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 217. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 218. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 219. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2024 (USD MILLION)
  • TABLE 220. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2025-2032 (USD MILLION)
  • TABLE 221. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 222. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 223. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2024 (USD MILLION)
  • TABLE 226. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2025-2032 (USD MILLION)
  • TABLE 227. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2024 (USD MILLION)
  • TABLE 228. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2025-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2024 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2025-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2024 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2025-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2024 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 250. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 251. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 252. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 253. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2024 (USD MILLION)
  • TABLE 254. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2025-2032 (USD MILLION)
  • TABLE 255. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 256. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 257. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2024 (USD MILLION)
  • TABLE 260. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2025-2032 (USD MILLION)
  • TABLE 261. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2024 (USD MILLION)
  • TABLE 262. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2025-2032 (USD MILLION)
  • TABLE 263. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 266. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 267. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 268. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 269. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2024 (USD MILLION)
  • TABLE 270. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2025-2032 (USD MILLION)
  • TABLE 271. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 272. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 273. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2024 (USD MILLION)
  • TABLE 276. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2025-2032 (USD MILLION)
  • TABLE 277. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2024 (USD MILLION)
  • TABLE 278. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2025-2032 (USD MILLION)
  • TABLE 295. BRICS RESORBABLE V